Catumaxomab: Clinical development and future directions

Catumaxomab, a monoclonal bispecific trifunctional antibody, was approved in the European Union in April 2009 for the intraperitoneal treatment of patients with malignant ascites. The marketing authorization holder Fresenius Biotech GmbH developed catumaxomab (Removab®) together with its partner TRI...

Full description

Saved in:
Bibliographic Details
Published in:mAbs 2010-03, Vol.2 (2), p.129-136
Main Authors: Linke, Rolf, Klein, Anke, Seimetz, Diane
Format: Article
Language:English
Subjects:
Animals
Antibodies, Bispecific - pharmacology
Antibodies, Bispecific - therapeutic use
Antigens, Neoplasm - immunology
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Binding
Biology
Bioscience
Calcium
Cancer
Carcinoma - drug therapy
Carcinoma - immunology
Carcinoma - pathology
Cell
Cell Adhesion Molecules - immunology
Cycle
Drug Discovery
Epithelial Cell Adhesion Molecule
European Union
Humans
Immunomodulation
Immunotherapy - trends
Landes
Mini-Reviews
Organogenesis
Peritoneal Neoplasms - drug therapy
Peritoneal Neoplasms - immunology
Peritoneal Neoplasms - pathology
Proteins
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Catumaxomab, a monoclonal bispecific trifunctional antibody, was approved in the European Union in April 2009 for the intraperitoneal treatment of patients with malignant ascites. The marketing authorization holder Fresenius Biotech GmbH developed catumaxomab (Removab®) together with its partner TRION Pharma GmbH, Germany. It is the first substance worldwide with a regulatory label for the treatment of malignant ascites due to epithelial carcinomas. Since the peritoneum is of mesothelial origin and therefore lacks EpCAM expression, the intraperitoneal administration of catumaxomab is an attractive targeted immunotherapeutic approach. Catumaxomab is able to destroy EpCAM positive tumor cells in the peritoneal cavity known as the main cause of malignant ascites. In addition, catumaxomab is a potential therapeutic option for several primary tumors since the EpCAM molecule is expressed on the majority of epithelial carcinomas. This review focuses on the clinical development of catumaxomab and indicates future directions.
ISSN:1942-0862
1942-0870
DOI:10.4161/mabs.2.2.11221